Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more
Leap Therapeutics Inc (LPTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -6.045x
Based on the latest financial reports, Leap Therapeutics Inc (LPTX) has a cash flow conversion efficiency ratio of -6.045x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.29 Million) by net assets ($2.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Leap Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Leap Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Leap Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Leap Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Feature Integration Technology Inc.
TWO:4951
|
0.090x |
|
WM Technology Inc
NASDAQ:MAPS
|
0.047x |
|
OUE Limited
F:OUE1
|
0.012x |
|
Ffbw Inc
OTCQX:FFBW
|
0.019x |
|
Groupe Pizzorno Environnement SA
PA:GPE
|
0.332x |
|
Mewah International Inc
F:MWX
|
-0.007x |
|
Calisa Acquisition Corp Ordinary shares
NASDAQ:ALIS
|
-3.299x |
|
Waratah Minerals Ltd
AU:WTM
|
-0.352x |
Annual Cash Flow Conversion Efficiency for Leap Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Leap Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.05 Million | $-60.30 Million | -1.720x | -136.49% |
| 2023-12-31 | $60.14 Million | $-43.75 Million | -0.728x | +18.95% |
| 2022-12-31 | $54.64 Million | $-49.04 Million | -0.898x | -175.43% |
| 2021-12-31 | $107.89 Million | $-35.16 Million | -0.326x | +15.38% |
| 2020-12-31 | $67.41 Million | $-25.96 Million | -0.385x | -102.50% |
| 2019-12-31 | $-1.75 Million | $-26.90 Million | 15.381x | +642.10% |
| 2018-12-31 | $9.18 Million | $-26.03 Million | -2.837x | -42.49% |
| 2017-12-31 | $11.12 Million | $-22.14 Million | -1.991x | -- |
| 2016-12-31 | $0.00 | $-25.34 Million | x | -- |
| 2015-12-31 | $26.87 Million | $-19.58 Million | -0.729x | -86.90% |
| 2014-12-31 | $46.21 Million | $-18.02 Million | -0.390x | +26.38% |
| 2013-12-31 | $18.77 Million | $-9.94 Million | -0.530x | +8.14% |
| 2012-12-31 | $13.10 Million | $-7.55 Million | -0.577x | -- |